肾臟去神经市场机会、成长动力、产业趋势分析和 2025 - 2034 年预测

2024 年全球肾臟去神经支配市场规模达到 11 亿美元，预计在 2025 年至 2034 年期间复合年增长率将达到 28%。随着对微创治疗的需求激增，医疗技术的快速进步进一步推动了肾臟去神经支配解决方案的采用率。

高血压，特别是难治性高血压已成为全球面临的重大健康挑战。传统治疗方法通常无法为难治性高血压患者带来有效的结果，因此迫切需要创新疗法。肾臟去神经支配术已成为治疗高血压的一种突破性的微创解决方案。在良好的临床试验结果的支持下，这项技术正在赢得医疗服务提供者和患者的信任，加速其广泛应用。

肾臟去神经支配系统的技术进步，包括射频消融和基于超音波的设备，显着提高了手术安全性和患者预后。这些创新扩大了治疗的可近性，为受无法控制的高血压困扰的患者带来了新的希望。此外，强调未治疗的高血压的风险和肾去神经支配的好处的宣传活动在刺激需求方面发挥关键作用。

根据技术，市场分为基于射频、基于超音波、基于微输注和其他系统。 2024 年，射频技术将占据主导地位，其普及度预计将以 29.3% 的复合年增长率增长，到 2034 年将达到 72 亿美元。广泛的临床研究及其广泛的可用性（特别是在发展中地区）进一步加强了其市场领导地位。

从最终用途来看，医院占 2024 年总收入的 62.3%，巩固了其作为市场主要贡献者的地位。医院提供先进的基础设施、熟练的专业人员以及确保手术成功的基本影像和监测工具。此外，它们也是临床试验、研究和训练的重要中心，加速了肾臟去神经支配尖端技术的采用。

光是美国肾臟去神经支配市场在 2024 年的价值就达到 4.072 亿美元，预计到 2034 年的复合年增长率将达到 26.6%。优惠的报销政策和对心血管健康项目的大量投资进一步促进了这一上升趋势。此外，正在进行的临床试验和研究计划继续建立信任和认识，巩固肾臟去神经支配作为高血压管理变革解决方案的地位。

目录

第 1 章：方法论与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 高血压和抗药性高血压盛行率不断上升
    • 人们对微创手术的认识不断提高
    • 肾臟去神经支配技术的进展
    • 临床试验结果良好，展现疗效与安全性
  • 产业陷阱与挑战
    • 对手术安全性和潜在併发症的担忧
• 成长潜力分析
• 监管格局
• 技术格局
• 差距分析
• 波特的分析
• PESTEL 分析
• 未来市场趋势
• 价值链分析

第四章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第 5 章：市场估计与预测：按技术，2021 - 2034 年

• 主要趋势
• 基于射频
• 基于超音波
• 基于微灌注
• 其他技术

第 6 章：市场估计与预测：按应用，2021 - 2034 年

• 主要趋势
• 高血压
• 慢性肾臟病
• 其他应用

第 7 章：市场估计与预测：按最终用途，2021 - 2034 年

• 主要趋势
• 医院
• 门诊手术中心
• 专科诊所

第 8 章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第九章：公司简介

• Abbott
• ABLATIVE SOLUTIONS
• Boston Scientific
• Johnson and Johnson
• Medtronic
• Otsuka
• Recor
• Symple Surgical
• TERUMO
• VENUS MEDTECH

The Global Renal Denervation Market reached USD 1.1 billion in 2024 and is poised to expand at a remarkable CAGR of 28% between 2025 and 2034. This growth is primarily driven by the rising prevalence of hypertension and the increasing incidence of drug-resistant cases. As demand for minimally invasive treatments surges, rapid advancements in medical technology are further propelling adoption rates of renal denervation solutions.

Hypertension, especially resistant hypertension, has become a critical global health challenge. Traditional treatments often fail to deliver effective outcomes for patients with drug-resistant hypertension, creating a pressing need for innovative therapies. Renal denervation has emerged as a groundbreaking, minimally invasive solution to manage high blood pressure. Supported by favorable clinical trial outcomes, this technology is gaining trust among healthcare providers and patients alike, accelerating its widespread adoption.

Technological advancements in renal denervation systems, including radiofrequency ablation and ultrasound-based devices, have significantly improved procedural safety and patient outcomes. These innovations have expanded treatment accessibility, offering new hope to patients who struggle with uncontrolled hypertension. Additionally, awareness initiatives highlighting the risks of untreated hypertension and the benefits of renal denervation are playing a pivotal role in boosting demand.

The market is segmented by technology into radiofrequency-based, ultrasound-based, micro-infusion-based, and other systems. Radiofrequency-based technology dominated the landscape in 2024, and its popularity is projected to grow at a CAGR of 29.3%, reaching USD 7.2 billion by 2034. Known for its safety, precision, and cost-effectiveness, radiofrequency technology delivers consistent results and remains the preferred choice for healthcare providers. Extensive clinical research and its widespread availability, particularly in developing regions, further strengthen its market leadership.

In terms of end use, hospitals accounted for 62.3% of the total revenue in 2024, cementing their role as key contributors to the market. Hospitals offer advanced infrastructure, skilled professionals, and essential imaging and monitoring tools that ensure successful procedures. Moreover, they serve as critical hubs for clinical trials, research, and training, accelerating the adoption of cutting-edge technologies in renal denervation.

The U.S. renal denervation market alone was valued at USD 407.2 million in 2024 and is forecast to grow at a CAGR of 26.6% through 2034. Rising healthcare expenditures related to hypertension management are driving the adoption of innovative treatment methods. Favorable reimbursement policies and significant investments in cardiovascular health programs further contribute to this upward trajectory. Additionally, ongoing clinical trials and research initiatives continue to build trust and awareness, solidifying renal denervation as a transformative solution for hypertension management.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of hypertension and drug-resistant hypertension
    • 3.2.1.2 Rising awareness about minimally invasive procedures
    • 3.2.1.3 Advancements in renal denervation technologies
    • 3.2.1.4 Favorable clinical trial outcomes showcasing efficacy and safety
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Concerns about procedural safety and potential complications
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
• 3.6 Gap analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis
• 3.9 Future market trends
• 3.10 Value chain analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Technology, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Radiofrequency based
• 5.3 Ultrasound based
• 5.4 Micro-Infusion based
• 5.5 Other technologies

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Hypertension
• 6.3 Chronic kidney disease
• 6.4 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ambulatory surgical centers
• 7.4 Specialty clinics

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Abbott
• 9.2 ABLATIVE SOLUTIONS
• 9.3 Boston Scientific
• 9.4 Johnson and Johnson
• 9.5 Medtronic
• 9.6 Otsuka
• 9.7 Recor
• 9.8 Symple Surgical
• 9.9 TERUMO
• 9.10 VENUS MEDTECH